An overactive bladder symptom and health-related quality of life short-form: Validation of the OAB-q SF


  • Conflict of Interest: Karin S. Coyne, Christine L. Thompson, and Chris C. Sexton are employed by Evidera (formerly a division of United BioSource Corporation), which provides consulting and other research services to pharmaceutical, device, government and non-government organizations. As Evidera employees, they work with a variety of companies and organizations and are expressly prohibited from receiving any payment or honoraria directly from these organizations for services rendered.
  • Funding Information: Funding for this work was provided by Pfizer. Karin S. Coyne, Chris C. Sexton, and Christine Thompson are employees of Evidera (formerly a division of United BioSource Corporation) who were paid consultants to Pfizer in connection with the development of this manuscript.



The Overactive Bladder Questionnaire (OAB-q) has demonstrated robust psychometric properties in continent and incontinent OAB patients. However, there is a need for a short-form of this instrument for settings where completing the full OAB-q may be too burdensome. The purpose of this manuscript is to describe the validation of the OAB-q short-form.


Three studies were used to derive and validate the OAB-q SF: a 12-week, multicenter, open-label clinical trial of tolterodine ER (N = 865 incontinent OAB [I-OAB]; the “Noble Nested Case-Control” [NCC] study; N = 523 healthy controls; N = 396 OAB); and a test–retest validation study (N = 47). Rasch analysis and confirmatory factor analysis (CFA) were performed to assess the subscale structure, and the psychometric performance of the resulting scales was evaluated.


Based on the Rasch analysis, 6-items were retained in the OAB-q SF Symptom Bother Scale and 13-items were retained in the HRQL scale. CFAs showed excellent model fit and internal consistency in the study populations. Both scales demonstrated good convergent validity, discriminant validity, internal reliability, reproducibility, and responsiveness to change. The OAB-q SF scales clearly differentiated among I-OAB, C-OAB, and healthy controls.


The OAB-q SF captures the full spectrum of OAB Symptom Bother and HRQL impact with good reliability, validity, and responsiveness, while being less time-consuming for patients to complete. Neurourol. Urodynam. 34:255–263, 2015. © 2014 Wiley Periodicals, Inc.